DEA schedule
Is everolimus a controlled substance?
Federal schedule for everolimus from the FDA NDC directory, checked against the DEA controlled substances list.
Source: FDA NDC Directory file dated 2026-10-22. Publisher page
No. Everolimus is not a federally controlled substance. None of its FDA NDC listings carries a DEA schedule, and everolimus is not on the DEA controlled substances list.
Run it in Rivvi
Which 2027 plans near you dropped or restricted everolimus?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Schedule check
| Source | What it lists |
|---|---|
| FDA NDC directory | 85 prescription listings from 15 labelers, none with a DEA schedule |
| DEA controlled substances list | everolimus is not on the list |
Everolimus NDC listings
| NDC | Product | Form | Strength | Labeler | DEA schedule |
|---|---|---|---|---|---|
| 0078-0567 | Afinitor | tablet | 10 mg/1 | Novartis Pharmaceuticals Corporation | None |
| 0078-0594 | Afinitor | tablet | 2.5 mg/1 | Novartis Pharmaceuticals Corporation | None |
| 0078-0566 | Afinitor | tablet | 5 mg/1 | Novartis Pharmaceuticals Corporation | None |
| 0078-0620 | Afinitor | tablet | 7.5 mg/1 | Novartis Pharmaceuticals Corporation | None |
| 0078-0626 | Afinitor Disperz | tablet, for suspension | 2 mg/1 | Novartis Pharmaceuticals Corporation | None |
| 0078-0627 | Afinitor Disperz | tablet, for suspension | 3 mg/1 | Novartis Pharmaceuticals Corporation | None |
| 0078-0628 | Afinitor Disperz | tablet, for suspension | 5 mg/1 | Novartis Pharmaceuticals Corporation | None |
| 0078-0417 | Zortress | tablet | .25 mg/1 | Novartis Pharmaceuticals Corporation | None |
| 0078-0414 | Zortress | tablet | .5 mg/1 | Novartis Pharmaceuticals Corporation | None |
| 0078-0415 | Zortress | tablet | .75 mg/1 | Novartis Pharmaceuticals Corporation | None |
| 0078-0422 | Zortress | tablet | 1 mg/1 | Novartis Pharmaceuticals Corporation | None |
| 0054-0470 | Everolimus | tablet | .25 mg/1 | Hikma Pharmaceuticals USA Inc. | None |
| 51991-379 | Everolimus | tablet | .25 mg/1 | Breckenridge Pharmaceutical, Inc. | None |
| 59651-931 | everolimus | tablet | .25 mg/1 | Aurobindo Pharma Limited | None |
| 63850-0062 | Everolimus | tablet | .25 mg/1 | Natco Pharma Limited | None |
| 67877-718 | Everolimus | tablet | .25 mg/1 | Ascend Laboratories, LLC | None |
| 70377-069 | Everolimus | tablet | .25 mg/1 | Biocon Pharma Inc. | None |
| 72319-003 | Everolimus | tablet | .25 mg/1 | i3 Pharmaceuticals, LLC | None |
| 0054-0471 | Everolimus | tablet | .5 mg/1 | Hikma Pharmaceuticals USA Inc. | None |
| 49884-159 | Everolimus | tablet | .5 mg/1 | Par Health USA, LLC | None |
| 51991-380 | Everolimus | tablet | .5 mg/1 | Breckenridge Pharmaceutical, Inc. | None |
| 59651-932 | everolimus | tablet | .5 mg/1 | Aurobindo Pharma Limited | None |
| 63850-0063 | Everolimus | tablet | .5 mg/1 | Natco Pharma Limited | None |
| 67877-719 | Everolimus | tablet | .5 mg/1 | Ascend Laboratories, LLC | None |
| 70377-070 | Everolimus | tablet | .5 mg/1 | Biocon Pharma Inc. | None |
| 72319-015 | Everolimus | tablet | .5 mg/1 | i3 Pharmaceuticals, LLC | None |
| 0054-0472 | Everolimus | tablet | .75 mg/1 | Hikma Pharmaceuticals USA Inc. | None |
| 51991-381 | Everolimus | tablet | .75 mg/1 | Breckenridge Pharmaceutical, Inc. | None |
| 59651-933 | everolimus | tablet | .75 mg/1 | Aurobindo Pharma Limited | None |
| 63850-0064 | Everolimus | tablet | .75 mg/1 | Natco Pharma Limited | None |
| 67877-720 | Everolimus | tablet | .75 mg/1 | Ascend Laboratories, LLC | None |
| 70377-071 | Everolimus | tablet | .75 mg/1 | Biocon Pharma Inc. | None |
| 72319-016 | Everolimus | tablet | .75 mg/1 | i3 Pharmaceuticals, LLC | None |
| 0054-0604 | Everolimus | tablet | 1 mg/1 | Hikma Pharmaceuticals USA Inc. | None |
| 49884-283 | Everolimus | tablet | 1 mg/1 | Par Health USA, LLC | None |
| 51991-985 | Everolimus | tablet | 1 mg/1 | Breckenridge Pharmaceutical, Inc. | None |
| 59651-934 | everolimus | tablet | 1 mg/1 | Aurobindo Pharma Limited | None |
| 63850-0107 | Everolimus | tablet | 1 mg/1 | Natco Pharma Limited | None |
| 67877-721 | Everolimus | tablet | 1 mg/1 | Ascend Laboratories, LLC | None |
| 70377-112 | Everolimus | tablet | 1 mg/1 | Biocon Pharma Inc. | None |
Showing 40 of 85 listings.
Questions
Is everolimus a controlled substance?
No. Everolimus is not a federally controlled substance. None of its FDA NDC listings carries a DEA schedule, and everolimus is not on the DEA controlled substances list.
Is everolimus a narcotic?
No. Everolimus is not on the DEA controlled substances list, so the DEA does not classify it as a narcotic. Its FDA established pharmacologic class is Kinase Inhibitor and mTOR Inhibitor Immunosuppressant.
Does this page cover state schedules?
No. This page reports the federal schedule only. Some states schedule drugs on their own; check your state board of pharmacy.
More on Everolimus
- What is Everolimus used for?FDA label uses
- Generic for Afinitor DisperzFDA Orange Book
- Generic for AfinitorFDA Orange Book
- Generic for ZortressFDA Orange Book
- Kinase Inhibitors listFDA drug class
- MTOR Inhibitor Immunosuppressants listFDA drug class
- NDC 0078-0414Everolimus NDC record
- NDC 0078-0415Everolimus NDC record
- NDC 0078-0417Everolimus NDC record